Format

Send to

Choose Destination
See comment in PubMed Commons below
Lung Cancer. 2005 Jul;49 Suppl 1:S37-40. Epub 2005 Apr 20.

CT, RECIST, and malignant pleural mesothelioma.

Author information

1
Department of Medicine and Pharmacology, University of Western Australia, Nedlands, WA 6009 Australia. anowak@cyllene.uwa.edu.au

Abstract

The unique growth pattern of malignant pleural mesothelioma (MPM) presents challenges for clinical investigators assessing tumour response to treatment. Assessment of response is an important surrogate for patient benefit, particularly in phase II clinical trials. Neither the previous WHO criteria nor the more recent RECIST criteria are well suited to tumour measurement in this disease. This paper discusses uni-dimensional measurement of tumour response in pleural mesothelioma, and the development and validation of the modified RECIST criteria for MPM, which attempt to overcome some of the shortcomings of the RECIST criteria in this setting.

PMID:
15950799
DOI:
10.1016/j.lungcan.2005.03.030
[Indexed for MEDLINE]
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Elsevier Science
    Loading ...
    Support Center